Ondansetron
- TRADE NAMES: Emeset; Oncoden; Zofran (GSK); Zofron; Zuplenz (Par)
- INDICATIONS: Nausea and vomiting
- CLASS: 5-HT3 antagonist, Antiemetic, Serotonin type 3 receptor antagonist
- HALF-LIFE: 3–6 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amisulpride, Apomorphine, Carbamazepine, Phenytoin, Ribociclib, Rifampin, Tramadol
PREGNANCY CATEGORY: B
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ondansetron in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/28/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
